Walleye Capital
IMDX icon

Walleye Capital’s Insight Molecular Diagnostics IMDX Stock Holding History

Walleye Capital’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$207K Buy
+57,587
New +$255K ﹤0.01% 4787
2020
Q4 		– Sell
-518
Closed -$14K – 1060
2020
Q3 		$14K Buy
+518
New +$14.9K ﹤0.01% 799

Other funds holding IMDX

AIC
AWM Investment Company New York $1.04B AUM 103.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Family Office Research
Family Office Research Bethesda, Maryland $260M AUM 20.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

Walleye Capital's IMDX Position: Q3 2026 in Review

Walleye Capital opened a new position in Insight Molecular Diagnostics (IMDX) in Q3 2026: 57,587 shares worth $207K. The stake represents ﹤0.01% of the portfolio and ranks #4787 among its holdings. This is a return to the name: Walleye Capital previously reported a position in IMDX as recently as Q3 2020.

Walleye Capital first reported a position in IMDX in Q3 2020 and has held it in 2 quarters since. 35 funds tracked by Wall St. Rank hold IMDX as of Q3 2026.

  • Walleye Capital held 57,587 shares of Insight Molecular Diagnostics worth $207K as of Q3 2026.
  • Insight Molecular Diagnostics was a new Walleye Capital position in Q3 2026.
  • Insight Molecular Diagnostics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #4787 holding.
  • Walleye Capital first reported a position in Insight Molecular Diagnostics in Q3 2020 and has held it in 2 quarters since.
  • 35 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.